AKTX - CIK 0001541157
The table below shows Akari Therapeutics Plc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.49M | -$2.15M | -$4.04M | -$4.88M | -$7.74M | $228.94K |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
Akari Therapeutics Plc reported operating cash flow of -$10.57M for fiscal year 2025. That is up 15.8% from -$12.55M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$24.62M (FY 2016) to -$10.57M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $53.00K | $2.13M | $1.51M | $3.21M | $9.88M | $157.74K |